Titan Pharmaceuticals closes $600K private placement of Series C convertible preferred stock

TITAN PHARMACEUTICALS INC

Raised $600K from Blue Harbour Asset Management via 60,000 shares of Series C convertible preferred at $10/share.
Conversion price set at $3.40 per share with a 19.99% beneficial ownership blocker.
ARC Group Ltd. served as sole financial advisor; shares sold under Regulation S, unregistered.
Registration rights agreement grants Blue Harbour potential future registration rights.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.